Merrimack Pharma: Annual Report 2014 (Merrimack) - Mar 8, 2015 - Anticipated patent expiry for composition of matter in US and ex-US in 2031 and 2032; Anticipated patent expiry for methods of use in US and ex-US in 2031 and 2032; Anticipated patent expiry for diagnostics in US, EU and ROW in 2032; Anticipated patent expiry for dosage and administration in 2035
Anticipated patent expiry • Oncology
|